

HETEROCYCLES, Vol. 78, No. 10, 2009, pp. 2579 - 2588. © The Japan Institute of Heterocyclic Chemistry  
Received, 18th May, 2009, Accepted, 18th June, 2009, Published online, 19th June, 2009  
DOI: 10.3987/COM-09-11759

## ONE-POT SYNTHESIS OF BENZOTRIAZOLES AND BENZOTRIAZOLE 1-OXIDES BY REDUCTIVE CYCLIZATION OF *o*-NITROPHENYLAZO COMPOUNDS WITH BENZYL ALCOHOL

Renata Farkas,<sup>a</sup> Mercedes Törincsi,<sup>a</sup> Pal Kolonits,<sup>a</sup> Oscar Jimenez Alonso,<sup>b</sup> and Lajos Novak<sup>\*a</sup>

<sup>a</sup>Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, Research Group for Alkaloid Chemistry, Hungarian Academy of Sciences, Gellért tér 4, 1111 Budapest, Hungary

Fax +36 (1)4633297; E-mail: lnovak@mail.bme.hu

<sup>b</sup>ISDIN, Diagonal 520, 08006 Barcelona, Spain

**Abstract** - Reductive cyclization of 2-[(2-nitrophenyl)azophenols **1** with benzyl alcohol and sodium hydroxide afforded 2-(2*H*-benzotriazol- 2-yl)phenols **3** and their 1-oxide **2** in good to excellent yields.


Benzotriazole derivatives serve as important precursor for the construction of heterocyclic ring systems.<sup>1-6</sup> Many of them have significant pharmaceutical activities.<sup>7-9</sup> The others have been used as building block for the preparation of UV light absorbers.<sup>10-14</sup>

For the preparation of benzotriazole derivatives, the most frequently used method is the reductive cyclization of *o*-nitroazobenzene derivatives (Scheme 1). The following reducing agents have been used: powdered zinc and NaOH in an aqueous MeOH,<sup>15</sup> hydrazine hydrate in the presence of NaOH,<sup>16,17</sup> catalytic hydrogenation over palladium on charcoal<sup>18-21</sup> or platinum sulfide on carbon<sup>22</sup> or on modified Raney Nickel,<sup>23,24</sup> with electrolytic reduction at a mercury electrode,<sup>25</sup> and formamidine sulfonic acid, and baker's yeast.<sup>27</sup>

The corresponding *N*-oxide **2** was an intermediate of the above reaction and could be prepared by the reduction of *o*-nitroazobenzene with glucose in alcoholic NaOH,<sup>28</sup> or with a mixture of sodium hydrosulfide and NaOH in toluene and water,<sup>29</sup> or with hydrazine hydrate in aqueous MeOH containing 2,3-dichloro-1,4-naphthoquinone.<sup>30</sup> The method using baker's yeast is also applicable for the preparation of *N*-oxide.<sup>27</sup>

In the course of developing novel scaffolds for medicinal and light absorbers application, we found that 2-aryl-2*H*-benzotriazoles **2**, **3** could be prepared from *o*-nitroazobenzene **1** without using any of the above listed reducing agents. Here we report in full experimental details of the new procedure and the related spectral data.

Our preparations of compounds **2** and **3** were based on the reducing properties of benzyl alcohol under basic condition. Treatment of a solution of azo compound **1a** in benzyl alcohol with NaOH at 80 °C afforded rather fast formation of the corresponding *N*-oxide **2a** and after 1.5 h this compound was isolated in good yield (Table 1, entry 1). However, when the reaction was performed at 150 °C, the initially formed *N*-oxide was transformed into benzotriazole **3a** which was then isolated in excellent yield (entry 2).



Scheme 1. Reagents: (a) benzyl alcohol, NaOH,  $t < 100^\circ\text{C}$ ;  
(b) benzyl alcohol, NaOH,  $t > 120^\circ\text{C}$

To explore the scope and versatility of this method the effect of various substituents on the benzotriazole skeleton and on the phenyl group were investigated.

As it can be seen in Table 1, neither the substitution of the benzotriazole (entries 7-12 and 13-16), nor the substituent of the phenyl group (entries 3-6, 9-12, and 13-16) affected significantly the yield of the reductive cyclization. In all cases, we got good or excellent yields.

In the above reactions benzyl alcohol acts as reducing agent. Namely, the process starts with single electron transfer from the oxygen to the nitro group and then proceeds according to the known reduction reactions of this group.

In summary, we have demonstrated that 2-aryl-2*H*-benzotriazoles can be prepared conveniently from readily available *o*-nitroazobenzene without using expensive reducing agents. This new method has the potential to be used in the synthesis of many other derivatives of benzotriazoles.

**Table 1** Compounds Prepared by the Reduction of **1a-h**

Entry	Substrate	Product	X	R	Temp (°C)	Time (h)	TLC <i>R</i> <sub>f</sub>	Mp (°C)	Yield <sup>a</sup> (%)
1	<b>1a</b>	<b>2a</b>	H	Me	80	1.5	0.45	143-45	90
2	<b>1a</b>	<b>3a</b>	H	Me	150	1	0.79	126-28	95
3	<b>1b</b>	<b>2b</b>	H	Ph	80	1.5	0.38	169-70	81
4	<b>1b</b>	<b>3b</b>	H	Ph	185	4	0.70	153-55	98
5	<b>1c</b>	<b>2c</b>	H	cyclohexyl	120	15	0.42	149-51	80
6	<b>1c</b>	<b>3c</b>	H	cyclohexyl	150	0.5	0.85	134-36	81
7	<b>1d</b>	<b>2d</b>	Cl	Me	80	2.5	0.51	173-75	52
8	<b>1d</b>	<b>3d</b>	Cl	Me	150	1	0.80	146-48	87
9	<b>1e</b>	<b>2e</b>	Cl	Ph	80	1.5	0.47	176-78	61
10	<b>1e</b>	<b>3e</b>	Cl	Ph	150	1	0.73	136-39	74
11	<b>1f</b>	<b>2f</b>	Cl	cyclohexyl	80	1.5	0.50	131-33	75
12	<b>1f</b>	<b>3f</b>	Cl	cyclohexyl	150	1.5	0.88	117-18	79
13	<b>1g</b>	<b>2g</b>	MeO	Me	80	1.5	0.33	133-35	69
14	<b>1g</b>	<b>3g</b>	MeO	Me	150	1	0.75	126-27	57
15	<b>1h</b>	<b>2h</b>	MeO	Ph	120	1.5	0.43	178-80	75
16	<b>1h</b>	<b>3h</b>	MeO	Ph	140	1.5	0.66	118-24	80

<sup>a</sup>Isolated and unoptimized yields.

## EXPERIMENTAL

Mps were determined on a Büchi apparatus and are uncorrected. IR spectra were recorded on Bruker Alpha FT Spectrophotometer. <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained on a Bruker DRX-500 spectrometer. All NMR spectra are reported in ppm relative to TMS. Merck precoated silica gel 60 F<sub>254</sub>

plates were used for TLC and Kieselgel 60 for column chromatography. A hexane-acetone 5:2 (v/v) mixture was used for TLC.

### Preparation of *N*-oxides 2; General Procedure

To a stirred solution of **1** (16 mmol) in freshly distilled benzyl alcohol (60 mL) was added pulverized NaOH (0.7 g, 18 mmol) and the resulting mixture was heated with stirring at the temperature and for the time given in Table 1. After cooling, water was added (25 mL), the mixture was acidified by the addition of 2N aqueous HCl and then extracted with CH<sub>2</sub>Cl<sub>2</sub> (3x25 mL). The combined organic layers were dried (MgSO<sub>4</sub>), concentrated in vacuum and the residue was dried under IR lamp.

### Preparation of Benzotriazoles 3; General Procedure

To a stirred solution of **1** (20 mmol) in freshly distilled benzyl alcohol (60 mL) was added NaOH powder (1.4 g, 35 mmol) and the resultant mixture was heated with stirring at the temperature and for the time given in Table 1. Evaporation of benzyl alcohol under reduced pressure provided a residue which was treated with water. The solids were collected by filtration and then washed successively with water and EtOH.

#### **2-(2*H*-1,2,3-Benzotriazol-2-yl)-4-methylphenol (2a)<sup>31</sup>**

IR (KBr): 3442 (OH), 1520, 1454, 1360, 1233, 1113 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 2.38 (s, 3H, CH<sub>3</sub>), 7.13 (d, *J*= 8.5 Hz, 1H, C<sub>6</sub>-H), 7.30 (dd, *J*= 8.5 and 1 Hz, 1H, C<sub>5</sub>-H), 7.47 (t, *J*= 8 Hz, 1H, C<sub>6'</sub>-H), 7.52 (t, *J*= 8 Hz, 1H, C<sub>5'</sub>-H), 7.57 (br. s, 1H, C<sub>3</sub>-H), 7.82 (d, *J*= 8.5 Hz, 1H, C<sub>7</sub>-H), 7.84 (d, *J*= 8.5 Hz, 1H, C<sub>4</sub>-H), 9.77 (s, 1H, OH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 20.37 (CH<sub>3</sub>), 113.27 (C-7'), 119.25 (C-4'), 121.17 (C-6), 124.95 (C-2), 126.09 (C-3), 126.48 (C-7a'), 127.94 (C-6), 129.26 (C-5'), 131.01 (C-4), 133.61 (C-5), 142.20 (C-3a'), 149.82 (C-1).

#### **3-(1-Oxido-2*H*-1,2,3-benzotriazol-2-yl)-3-biphenylol (2b)**

IR (KBr): 3441 (OH), 1615, 1520, 1449, 1381, 1298, 1114 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 7.31 (d, *J*= 8.5 Hz, 1H, C<sub>5</sub>-H), 7.35 (t, *J*= 7.5 Hz, 1H, C<sub>10</sub>-H), 7.44 (t, *J*= 7.5 Hz, 2H, C<sub>9</sub>-H and C<sub>11</sub>-H), 7.50 (t, *J*= 8 Hz, 1H, C<sub>6'</sub>-H), 7.54 (m-t, *J*= 8 Hz, 1H, C<sub>5'</sub>-H), 7.60 (d, *J*= 7.5 Hz, 2H, C<sub>8</sub>-H and C<sub>12</sub>-H), 7.74 (d, *J*= 8.5 Hz, 1H, C<sub>6</sub>-H), 7.85 (d, *J*= 8.3 Hz, 1H, C<sub>7</sub>-H), 7.87 (d, *J*= 8.6 Hz, 1H, C<sub>4</sub>-H), 8.01 (s, 1H, C<sub>2</sub>-H), 10.12 (s, 1H, OH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 113.30 (C-7'), 119.35 (C-4'), 121.81 (C-5), 124.66 (C-2), 125.63 (C-3), 126.59 (C-7a'), 126.86 (C-8 and C-12), 127.46 (C-10), 128.51 (C-6'), 128.91 (C-9 and C-11), 129.41 (C-5'), 131.39 (C-6), 134.78 (C-1), 139.28 (C-7), 142.36 (C-3a'), 151.43 (C-4).

*Anal.* Calcd for C<sub>18</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub>: C, 71.28; H, 4.32; N, 13.85. Found: C, 71.04; H, 4.55; N, 13.67.

**4-Cyclohexyl-2-(1-oxido-2*H*-1,2,3-benzotriazol-2-yl)phenol (2c)**

IR (KBr): 3442 (OH), 1614, 1505, 1457, 1388, 1254, 1105 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 1.26 (m, 1H, C<sub>4</sub>''-H), 1.41 (m, 2H, C<sub>3</sub>''-H and C<sub>5</sub>''-H), 1.43 (m, 2H, C<sub>2</sub>''-H and C<sub>6</sub>''-H), 1.75 (m, 1H, C<sub>4</sub>''-H), 1.85 (m, 2H, C<sub>3</sub>''-H and C<sub>5</sub>''-H), 1.92 (m, 2H, C<sub>2</sub>''-H and C<sub>6</sub>''-H), 2.56 (m, 1H, C<sub>1</sub>''-H), 7.00 (br.s, 1H, OH), 7.16 (d, *J*= 8.4 Hz, 1H, C<sub>6</sub>-H), 7.36 (d, *J*= 8.4 Hz, 1H, C<sub>5</sub>-H), 7.49 (t, *J*= 8.0 Hz, 1H, C<sub>6</sub>'-H), 7.53 (t, *J*= 8.0 Hz, 1H, C<sub>5</sub>'-H), 7.60 (s, 1H, C<sub>3</sub>-H), 7.84 (d, *J*= 8.6 Hz, 1H, C<sub>7</sub>'-H), 7.87 (d, *J*= 8.8 Hz, 1H, C<sub>4</sub>'-H).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 26.03 (C-4''), 26.79 (C-3'' and C-5''), 34.51 (C-2'' and C-6''), 43.56 (C-1''), 113.30 (C-7''), 119.29 (C-4'), 121.21 (C-6), 124.11 (C-3), 125.04 (C-2), 126.53 (C-7a'), 127.94 (C-6'), 129.23 (C-5'), 131.49 (C-5), 141.49 (C-4), 142.22 (C-3a'), 149.98 (C-1).

*Anal.* Calcd for C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>: C, 69.88; H, 6.19; N, 13.58. Found: C, 70.11; H, 6.34, N, 13.36.

**2-(6-Chloro-1-oxido-2*H*-1,2,3-benzotriazol-2-yl)-4-methylphenol (2d)<sup>28</sup>**

IR (KBr): 3441 (OH), 1616, 1509, 1498, 1362, 1254, 1123 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 2.38 (s, 3H, CH<sub>3</sub>), 7.13 (d, *J*= 8.4 Hz, 1H, C<sub>6</sub>-H), 7.32 (dd, *J*= 8.4 and 1.0 Hz, 1H, C<sub>5</sub>-H), 7.46 (dd, *J*= 8.4 and 1.5 Hz, 1H, C<sub>5</sub>'-H), 7.54 (br. s, 1H, C<sub>3</sub>-H), 7.80 (d, *J*= 9.2 Hz, 1H, C<sub>4</sub>'-H), 7.84 (br. s, 1H, C<sub>7</sub>'-H), 9.26 (br. s, 1H, OH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 20.38 (CH<sub>3</sub>), 112.47 (C-7''), 120.53 (C-4'), 121.31 (C-6), 124.81 (C-2), 126.01 (C-3), 126.58 (C-7a'), 131.10 (C-5'), 131.19 (C-4), 133.81 (C-5), 134.28 (C-6'), 140.58 (C-3a'), 149.79 (C-1).

**3-(6-Chloro-1-oxido-2*H*-1,2,3-benzotriazol-2-yl)-4-biphenylol (2e)**

IR (KBr): 3440 (OH), 1500, 1447, 1358, 1233, 1121 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 7.31 (d, *J*= 8.6 Hz, 1H, C<sub>5</sub>-H), 7.36 (t, *J*= 7.2 Hz, 1H, C<sub>10</sub>-H), 7.45 (t, *J*= 7.2 Hz, 2H, C<sub>9</sub>-H and C<sub>11</sub>-H), 7.47 (d, *J*= 7.9 Hz, 1H, C<sub>5</sub>'-H), 7.60 (dd, *J*= 8.5 and 1 Hz, 2H, C<sub>8</sub>-H and C<sub>12</sub>-H), 7.76 (dd, *J*= 8.5 and 2 Hz, 1H, C<sub>5</sub>-H), 7.82 (d, *J*= 9.1 Hz, 1H, C<sub>4</sub>'-H), 7.88 (br. s, 1H, C<sub>7</sub>'-H), 7.98 (d, *J*= 2 Hz, 1H, C<sub>2</sub>-H), 9.89 (s, 1H, OH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 112.49 (C-7''), 120.62 (C-4'), 121.94 (C-5), 124.58 (C-2), 125.49 (C-3), 126.70 (C-7a'), 126.88 (C-8 and C-12), 127.57 (C-10), 128.96 (C-9 and C-11), 131.28 (C-5'), 131.67 (C-6), 134.56 (C-6), 134.98 (C-1), 139.18 (C-7), 140.74 (C-3a'), 151.38 (C-4).

*Anal.* Calcd for C<sub>18</sub>H<sub>12</sub>ClN<sub>3</sub>O<sub>2</sub>: C, 64.01; H, 3.58; N, 12.44. Found: C, 63.92; H, 3.77, N, 12.21.

**2-(6-Chloro-1-oxido-2*H*-1,2,3-benzotriazol-2-yl)-4-cyclohexylphenol (2f)**

IR (KBr): 3440 (OH), 1500, 1447, 1358, 1233, 1121 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 1.26 (m, 1H, C<sub>4</sub>''-H), 1.40 (m, 2H, C<sub>3</sub>''-H and C<sub>5</sub>''-H), 1.42 (m, 2H, C<sub>2</sub>''-H and C<sub>6</sub>''-H), 1.75 (m, 2H, C<sub>4</sub>''-H), 1.86 (m, 2H, C<sub>3</sub>''-H and C<sub>5</sub>''-H), 1.91 (m, 2H, C<sub>2</sub>''-H and C<sub>6</sub>''-H), 2.55 (m, 1H, C<sub>1</sub>''-H), 7.15 (d, *J*= 8.5 Hz, 1H, C<sub>6</sub>-H), 7.37 (d, *J*= 8.2 Hz, 1H, C<sub>5</sub>-H), 7.46 (d, *J*= 9.1 Hz, 1H, C<sub>3</sub>'-H), 7.56

s, 1H, C<sub>3</sub>-H), 7.81 (d, *J*= 9.1 Hz, 1H, C<sub>4'</sub>-H), 7.85 (s, 1H, C<sub>7'</sub>-H), 8.0 (br. s, 1H, OH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 26.41 (C-4''), 27.17 (C-3'' and C-5''), 34.90 (C-2'' and C-6''), 43.93 (C-1''), 112.87 (C-7'), 120.94 (C-4'), 121.71 (C-6), 124.41 (C-3), 125.28 (C-2), 127.00 (C-7a'), 131.45 (C-5'), 132.17 (C-5), 134.65 (C-6'), 140.96 (C-3a'), 142.03 (C-4), 150.36 (C-1).

*Anal.* Calcd for C<sub>18</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>2</sub>: C, 62.88; H, 5.28; N, 12.22. Found: C, 62.59; H, 5.02; N, 12.49.

### 2-(6-Methoxy-1-oxido-2*H*-1,2,3-benzotriazol-2-yl)-4-methylphenol (2g)

IR (KBr): 3441 (OH), 1632, 1529, 1511, 1469, 1341, 1275, 1225, 1114 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 2.38 (s, 3H, CH<sub>3</sub>), 3.94 (s, 3H, OCH<sub>3</sub>), 6.98 (d, *J*= 1.7 Hz, 1H, C<sub>7'</sub>-H), 7.12 (d, *J*= 8.4 Hz, 1H, C<sub>6</sub>-H), 7.19 (dd, *J*= 9.4 and 2.2 Hz, 1H, C<sub>5'</sub>-H), 7.29 ((d, *J*= 8.5 Hz, 1H, C<sub>5</sub>-H), 7.52 (s, 1H, C<sub>3</sub>-H), 7.71 (d, *J*= 9.4 Hz, 1H, C<sub>4'</sub>-H), 10.00 (br. s, 1H, OH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 20.39 (CH<sub>3</sub>), 56.14 (OCH<sub>3</sub>), 89.71 (C-7'), 120.28 (C-4'), 121.14 (C-6), 124.93 (C-5'), 125.23 (C-2), 125.91 (C-3), 127.27 (C-7a'), 130.89 (C-4), 133.29 (C-5), 138.89 (C-3a'), 149.74 (C-1), 160.15 (C-6').

*Anal.* Calcd for C<sub>14</sub>H<sub>13</sub>N<sub>3</sub>O<sub>3</sub>: C, 61.99; H, 4.83; N, 15.49. Found: C, 62.21; H, 4.63; N, 15.25.

### 3-(6-Methoxy-1-oxydo-2*H*-1,2,3-benzotriazol-2-yl)-4-biphenylol (2h)

IR (KBr): 3440 (OH), 1632, 1620, 1526, 1488, 1378, 1285, 1224, 1014 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 3.59 (s, 3H, OCH<sub>3</sub>), 6.99 (s, 1H, C<sub>7</sub>-H), 7.19 (dd, *J*= 9.4 and 1.7 Hz, 1H, C<sub>5'</sub>-H), 7.29 (d, *J*= 8.5 Hz, 1H, C<sub>5</sub>-H), 7.35 (t, *J*= 7.4 Hz, 1H, C<sub>10</sub>-H), 7.44 (t, *J*= 7.5 Hz, 2H, C<sub>9</sub>-H and C<sub>11</sub>-H), 7.60 (d, *J*= 7.7 Hz, 2H, C<sub>8</sub>-H and C<sub>12</sub>-H), 7.71 (dd, *J*= 8.4 and 1.6 Hz, 1H, C<sub>6</sub>-H), 7.73 (d, *J*= 9.4, 1H, C<sub>4'</sub>-H), 7.95 (s, 1H, C<sub>2</sub>-H), 8.00 (br. s, 1H, OH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 56.16 (OCH<sub>3</sub>), 89.63 (C-7'), 120.34 (C-4'), 121.72 (C-5), 124.47 (C-2), 125.08 (C-5'), 125.86 (C-3), 126.85 (C-8 and C-12), 127.40 (C-7a'), 128.90 (C-9 and C-11), 131.05 (6), 134.63 (C-1), 139.02 (C-3a'), 139.37 (C-7), 151.36 (C-4), 160.30 (C-6').

*Anal.* Calcd for C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub>: C, 68.46; H, 4.54; N, 12.61. Found: C, 68.52; H, 4.43; N, 12.82.

### 2-(2*H*-1,2,3-Benzotriazol-2-yl)-4-methoxyphenol (3a)<sup>31</sup>

IR (KBr): 3441 (OH), 1615, 1599, 1514, 1473, 1348, 1304, 1251, 1131 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 2.41 (s, 3H, CH<sub>3</sub>), 7.09 (d, *J*= 8.4 Hz, 1H, C<sub>6</sub>-H), 7.16 (d, *J*= 8.4 Hz, 1H, C<sub>5</sub>-H), 7.49 (dd, *J*= 8.4 and 3.0 Hz, 2H, C<sub>5'</sub>-H and C<sub>6'</sub>-H), 7.94 (dd, *J*= 6.6 and 3.0 Hz, 2H, C<sub>4'</sub>-H and C<sub>7'</sub>-H), 8.22 (s, 1H, C<sub>3</sub>-H), 11.11 (s, 1H, OH).

### 3-(2*H*-1,2,3-Benzotriazol-2-yl)-4-biphenylol (3b)<sup>11</sup>

IR (KBr): 3441 (OH), 1615, 1596, 1484, 1355, 1225, 1133 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 7.27 (d, *J*= 8.5 Hz, 1H, C<sub>5</sub>-H), 7.35 (t, *J*= 7.3 Hz, 1H, C<sub>10</sub>-H), 7.46 (t, *J*= 7.5 Hz, 2H, C<sub>9</sub>-H and C<sub>11</sub>-H), 7.49 (dd, *J*= 6.5 and 3.0 Hz, 2H, C<sub>5'</sub>-H and C<sub>6'</sub>-H), 7.59 (d, *J*= 8.5 Hz, 1H, C<sub>5</sub>-H), 7.66 (d, *J*= 7.5 Hz, 2H, C<sub>8</sub>-H and C<sub>12</sub>-H), 7.93 (dd, *J*= 6.5 and 3.0 Hz, 2H, C<sub>4'</sub>-H and C<sub>7'</sub>-H), 8.65 (d, *J*=

1.8 Hz, 1H, C<sub>2</sub>-H), 11.37 (s, 1H, OH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 117.71 (C-4' and C-7'), 119.42 (C-5), 119.48 (C-2), 125.44 (C-3), 126.79 (C-8), 127.24 (C-10), 127.81 (C-5' and C-6'), 128.86 (C-9 and C-11), 129.04 (C-6), 133.48 (C-1), 139.72 (C-7), 142.87 (C-3a' and C-7a'), 149.17 (C-4).

### 2-(2*H*-1,2,3-Benzotriazol-2-yl)-4-cyclohexylphenol (3c)<sup>11</sup>

IR (KBr): 3442 (OH), 1616, 1595, 1515, 1448, 1351, 1254, 1220, 1132 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 1.29 (m, 1H, C<sub>4</sub>''-H), 1.43 (m, 2H, C<sub>3</sub>''-H and C<sub>5</sub>''-H), 1.47 (m, 2H, C<sub>2</sub>''-H and C<sub>6</sub>''-H), 1.76 (d, *J*= 12.5 Hz, 1H, C<sub>4</sub>''-H), 1.86 (d, *J*= 12.5 Hz, 2H, C<sub>3</sub>''-H and C<sub>5</sub>''-H), 1.94 (d, *J*= 12.5 Hz, 2H, C<sub>2</sub>''-H and C<sub>6</sub>''-H), 2.57 (m, 1H, C<sub>1</sub>''-H), 7.12 (d, *J*= 8.5 Hz, 1H, C<sub>6</sub>-H), 7.20 (dd, *J*= 8.5 and 0.9 Hz, 1H, C<sub>5</sub>-H), 7.47 (dd, *J*= 6.5 and 2.9 Hz, 2H, C<sub>5</sub>'-H and C<sub>6</sub>'-H), 7.93 (dd, *J*= 6.5 and 2.9 Hz, 2H, C<sub>4</sub>'-H and C<sub>7</sub>'-H), 8.24 (d, *J*= 0.8 Hz, 1H, C<sub>3</sub>-H), 11.13 (s, 1H, OH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 26.09 (C-4''), 26.88 (C-3'' and C-5''), 34.58 (C-2'' and C-6''), 43.74 (C-1''), 117.67 (C-4' and C-7'), 118.75 (C-6), 119.03 (C-3), 124.95 (C-2), 127.61 (C-5' and C-6'), 129.12 (C-5), 140.20 (C-4), 142.81 (C-3a' and C-7a'), 147.75 (C-1).

### 2-(5-Chloro-2*H*-1,2,3-benzotriazol-2-yl)-4-methylphenol (3d)<sup>28</sup>

IR (KBr): 3442 (OH), 1618, 1596, 1516, 1383, 1236, 1053 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 2.38 (s, 3H, CH<sub>3</sub>), 7.07 (d, *J*= 8.3 Hz, 1H, C<sub>6</sub>-H), 7.14 (d, *J*= 8.3 Hz, 1H, C<sub>5</sub>-H), 7.40 (dd, *J*= 8.1 and 0.9 Hz, 1H, C<sub>5</sub>'-H), 7.84 (d, *J*= 8.8 Hz, 1H, C<sub>4</sub>'-H), 7.88 (s, 1H, C<sub>7</sub>'-H), 8.12 (s, 1H, C<sub>3</sub>-H), 10.83 (s, 1H, OH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 20.53 (CH<sub>3</sub>), 116.65 (C-7'), 118.77 (C-4'), 118.85 (C-6), 121.09 (C-3), 124.60 (C-2), 129.18 (C-5'), 129.77 (C-4), 131.62 (C-5), 133.53 (C-6'), 141.29 (C-3a'), 143.12 (C-7a'), 147.48 (C-1).

### 3-(5-Chloro-2*H*-1,2,3-benzotriazol-2-yl)-4-biphenylool (3e)

IR (KBr): 3442 (OH), 1613, 1593, 1482, 1391, 1242, 1057 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 7.26 (d, *J*= 8.1 Hz, 1H, C<sub>5</sub>-H), 7.36 (d, *J*= 7.5 Hz, 1H, C<sub>10</sub>-H), 7.43 (dd, *J*= 9.0 and 1.0 Hz, 1H, C<sub>6</sub>'-H), 7.46 (t, *J*= 8.0 Hz, 2H, C<sub>9</sub>-H and C<sub>11</sub>-H), 7.60 (dd, *J*= 8.5 and 2.0 Hz, 1H, C<sub>6</sub>-H), 7.65 (d, *J*= 7.6 Hz, 2H, C<sub>8</sub>-H and C<sub>12</sub>-H), 7.88 (d, *J*= 9.1 Hz, 1H, C<sub>7</sub>'-H), 7.93 (d, *J*= 1.0 Hz, 1H, C<sub>4</sub>'-H), 8.61 (d, *J*= 2.0 Hz, 1H, C<sub>2</sub>-H), 11.10 (s, 1H, OH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 116.73 (C-4'), 118.87 (C-7'), 119.50 (C-5), 119.54 (C-2), 125.24 (C-3), 126.78 (C-8 and C-12), 127.33 (C-10), 128.90 (C-9 and C-11), 129.40 (C-6 and C-6'), 133.62 (C-1), 133.75 (C-5'), 139.59 (C-7), 141.39 (C-7a'), 143.22 (C-3a'), 149.12 (C-4).

*Anal.* Calcd for C<sub>18</sub>H<sub>12</sub>ClN<sub>3</sub>O: C, 67.19; H, 3.76; N, 13.06. Found: C, 67.02; H, 3.58; N, 13.01.

### 2-(5-Chloro-2*H*-1,2,3-benzotriazol-2-yl)-4-cyclohexylphenol (3f)

IR (KBr): 3440 (OH), 1618, 1596, 1449, 1348, 1253, 1048 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 1.28 (m, 1H, C<sub>4</sub>-H), 1.43 (m, 2H, C<sub>3</sub>-H and C<sub>5</sub>-H), 1.47 (m, 2H, C<sub>2</sub>-H and C<sub>6</sub>-H), 1.77 (m, 1H, C<sub>4</sub>-H), 1.87 (m, 2H, C<sub>3</sub>-H and C<sub>5</sub>-H), 1.93 (m, 2H, C<sub>2</sub>-H and C<sub>6</sub>-H), 2.57 (m, 1H, C<sub>1</sub>-H), 7.11 (d, *J*= 8.4 Hz, 1H, C<sub>6</sub>-H), 7.21 (d, *J*= 8.0 Hz, 1H, C<sub>5</sub>-H), 7.42 (d, *J*= 9.0 Hz, 1H, C<sub>5</sub>-H), 7.87 (d, *J*= 9.0 Hz, 1H, C<sub>4</sub>-H), 7.93 (s, 1H, C<sub>7</sub>-H), 8.20 (s, 1H, C<sub>3</sub>-H), 10.88 (br. s, 1H, OH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 26.07 (C-4"), 26.85 (C-3" and C-5"), 34.56 (C-2" and C-6"), 43.71 (C-1"), 116.69 (C-7'), 118.83 (C-4'), 118.87 (C-6), 119.04 (C-3), 124.76 (C-2), 129.19 (C-5'), 129.52 (C-5), 133.53 (C-6'), 140.36 (4), 141.34 (C-3a'), 143.17 (C-7a'), 147.72 (C-1).

*Anal.* Calcd for C<sub>18</sub>H<sub>18</sub>ClN<sub>3</sub>O: C, 65.95; H, 5.53; N, 12.82. Found: C, 66.13; H, 5.32; N, 12.59.

### 2-(5-Methoxy-2*H*-1,2,3-benzotriazol-2-yl)-4-methylphenol (3g)<sup>11</sup>

IR (KBr): 3441 (OH), 1630, 1521, 1437, 1302, 1228, 1123, 1026 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 2.31 (s, 3H, CH<sub>3</sub>), 3.88 (s, 3H, OCH<sub>3</sub>), 7.05 (d, *J*= 8.0 Hz, 1H, C<sub>6</sub>-H), 7.17 (d, *J*= 9.0 Hz, 1H, C<sub>6</sub>-H), 7.19 (d, *J*= 9.0 Hz, 1H, C<sub>5</sub>-H), 7.33 (s, 1H, C<sub>4</sub>-H), 7.67 (s, 1H, C<sub>3</sub>-H), 7.91 (d, *J*= 9.0 Hz, 1H, C<sub>7</sub>-H), 10.40 (br. s, 1H, OH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 20.07 (CH<sub>3</sub>), 55.88 (OCH<sub>3</sub>), 95.06 (C-4'), 118.10 (C-6), 118.96 (C-7'), 122.28 (C-6'), 124.24 (C-3), 126.58(C-2), 128.50 (C-4), 131.28 (C-5), 139.61 (C-7a'), 144.58 (C-3a'), 148.2 (C-1), 159.10 (C-5').

### 3-(5-Methoxy-2*H*-1,2,3-benzotriazol-2-yl)-4-biphenylol (3h)

IR (KBr): 3450 (OH), 1624, 1614, 1500, 1310, 1140 cm<sup>-1</sup>.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 3.89 (s, 3H, OCH<sub>3</sub>), 7.10 (s, 1H, C<sub>4</sub>-H), 7.13 (d, *J*= 9.2 Hz, 1H, C<sub>6</sub>-H), 7.23 (d, *J*= 8.6 Hz, 1H, C<sub>5</sub>-H), 7.34 (t, *J*= 7.3 Hz, 1H, C<sub>10</sub>-H), 7.44 (t, *J*= 7.5 Hz, 2H, C<sub>9</sub>-H and C<sub>11</sub>-H), 7.54 (d, *J*= 8.6 Hz, 1H, C<sub>6</sub>-H), 7.65 (d, *J*= 7.5 Hz, 2H, C<sub>8</sub>-H and C<sub>12</sub>-H), 7.77 (d, *J*= 9.2 Hz, 1H, C<sub>7</sub>-H), 8.56 (s, 1H, C<sub>2</sub>-H), 11.31 (s, 1H, OH).

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 55.64 (OCH<sub>3</sub>), 94.17 (C-4'), 118.46 (C-7'), 118.99 (C-2), 119.25 (C-5), 122.98 (C-6'), 125.53 (C-3), 126.76 (C-8 and C-12), 127.15 (C-10), 128.40 (C-6), 128.82 (C-9 and C-11), 133.33 (C-1), 139.02 (C-7a'), 139.81 (C-7), 143.94 (C-3a'), 148.74 (C-4), 159.81 (C-5').

*Anal.* Calcd for C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub>: C, 71.91; H, 4.76; N, 13.24. Found: C, 71.70; H, 4.55; N, 13.31.

## ACKNOWLEDGEMENT

The financial support for this investigation was provided by ISDIN. S. A. (Barcelona, Spain) and is greatly appreciated.

## REFERENCES

1. K. H. Saunders and R. L. M. Allen, 'Aromatic Diazo Compounds', E. Arnold Ltd. London, 3rd ed, 1985.

2. A. F. Hegarty, 'The Chemistry of Diazonium and Diaza groups', ed. by S. Patai, Part 2, John Wiley & Sons, New York, 1978, pp. 545-551.
3. I. Szele and H. Zollinger, *Topics in Current Chemistry*, 1983, **112**, 1; J. R Penton, *Helv. Chim. Acta*, 1982, **65**, 122; D. Bahulayan, L. John, and M. Lalithambika, *Synth. Commun.*, 2003, **33**, 863; H. A. Dabbagh, A. Teimouri, and A. N. Chermahini, *Dyes and Pigments*, 2007, **73**, 239; and references cited therein.
4. A. R. Katritzky, S. Rachwal, and G. J. Hitchings, *Tetrahedron*, 1991, **47**, 2683.
5. A. R. Katritzky, X. Lan, J. Z. Yang, and O. Denisko, *Chem. Rev.*, 1998, **98**, 409.
6. A. R. Katritzky, *J. Heterocycl. Chem.*, 1999, **36**, 1501.
7. G. Scapin, S. B. Patel, J. W. Becker, Q. Wang, C. Desponts, D. Waddleton, K. Skorey, W. Cromlish, Ch. Bayly, and M. Therien, *Biochemistry*, 2003, **42**, 11451.
8. P. G. Baraldi, R. Makaeva, M. G. Pavani, M. Del Carmen Nunez, G. Spallato, S. Moro, S. Falzoni, F. DiVirgilio, and R. Romagnoli, *Arzneimittel-Forschung*, 2002, **52**, 273.
9. F. Al-Omran, R. M. Mohareb, M. Rafat, and A. A. El-Khair, *J. Heterocycl. Chem.*, 2002, **39**, 877.
10. A. G. Koutsimpelis, C. G. Screttas, and O. Igglessi-Markopoulou, *Heterocycles*, 2005, **65**, 1393.
11. C. Trullas, C. Pelejero, J. Corbera, O. Jimenez, and L. Novak, *Spain Pat. Appl.*, (2008), ES 2300199 A1 20080601.
12. K. Golz-Berner, L. Zastrow, and S. Miton, *Ger. Pat. Appl.*, (2008), DE 102007010861 A1 20080904.
13. E. Woldt and S. Schmidt, *U.S. Pat. Appl.*, (2006), US 2006084754 A1 20060420.
14. A. Goeppel, *Eur. Pat. Appl.*, (2003), EP 1308153 A2 20030507.
15. M. F. Bruno, *US Patent*, 3018269 (1962) (*Chem. Abstr.*, 1962, **57**, 6147).
16. Ciba-Geigy AG, *Fr. Demande*, 2 292708 (1976) (*Chem. Abstr.*, 1977, **86**, 189953).
17. J. Rody and A. C. Rochat, *German Patent*, 2454889 (1975) (*Chem. Abstr.*, 1975, **93**, 8181).
18. A. C. Ziegler and, H. J. Peterli, *Swiss Patent*, 615165 (1980) (*Chem. Abstr.*, 1980, **93**, 8181).
19. S. Kintopf and U. Kress, *German Patent*, 2620970 (1976) (*Chem. Abstr.*, 1977, **86**, 89835).
20. K. Nakajima, T. Hiiro, and Y. Hukuda, *Japan. Kokai*, 1977, **77**, 113974 (*Chem. Abstr.*, 1978, **88**, 105347).
21. C. E. Ziegler, *Swiss Patent*, 615166 (1980) (*Chem. Abstr.*, 1980, **93**, 8179).
22. E. H. Jancis, *German Patent*, 2455155 (1975) (*Chem. Abstr.*, 1975, **83**, 115994).
23. H. L. White and C. V. Krolewski, *German Patent*, 2620896 (1976) (*Chem. Abstr.*, 1977, **86**, 106598).
24. H. L. White and C. V. Krolewski, *German Patent*, 615167 (1980) (*Chem. Abstr.*, 1980, **93**, 8180).
25. R. Bourgeois, A. Delay, R. Hazard, and A. Tallec, *Electrochim. Acta*, 1977, **22**, 857.
26. S. Tanimoto and T. Kamano, *Synthesis*, 1986, 647.
27. W. Baik, T. H. Park, B. H. Kim, and Y. M. Jun, *J. Org. Chem.*, 1995, **60**, 5883.

28. J. Rosevear and J. F. K. Wilshire, *Aust. J. Chem.*, 1982, **35**, 2089.
29. J. Roberts and W. B. Hardy, *U.S. Patent* 4224451 (1980) (*Chem. Abstr.*, 1981, **94**, 121545).
30. Y. Wakisaka and M. Sumitani, *Japan. Kokai*, 78 63379 (1978) (*Chem. Abstr.*, 1978, **89**, 180008).
31. W. Baik, T. H. Park, R. H. Kim, and Y. M. Yun, *J. Org. Chem.*, 1995, **60**, 5683.